DiaMedica Therapeutics Inc.(DMAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DMAC DiaMedica Therapeutics Inc.

Not Yet Opened 12-18 16:00:00 EST

8.31

+0.10

+1.22%

盘后8.55

+0.24+2.89%

19:24 EST

High8.47	Low8.00	Vol1.76M
Open8.47	D1 Closing8.21	Amplitude5.72%
Mkt Cap432.76M	Tradable Cap273.77M	Total Shares52.08M
T/O14.26M	T/O Rate5.34%	Tradable Shares32.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DMAC","market":"US","secType":"STK","nameCN":"DiaMedica Therapeutics Inc.","latestPrice":8.31,"timestamp":1766091600000,"preClose":8.21,"halted":0,"volume":1758909,"hourTrading":{"tag":"盘后","latestPrice":8.55,"preClose":8.31,"latestTime":"19:24 EST","volume":5286,"amount":44188.1801,"timestamp":1766103868205},"delay":0,"floatShares":32944600,"shares":52077439,"eps":-0.716181,"marketStatus":"Not Yet Opened","change":0.1,"latestTime":"12-18 16:00:00 EST","open":8.47,"high":8.47,"low":8,"amount":14261665.104705,"amplitude":0.057247,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.716181,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1544158800000,"exchange":"NASDAQ","adjPreClose":8.21,"preHourTrading":{"tag":"盘前","latestPrice":8.9165,"preClose":8.21,"latestTime":"08:46 EST","volume":515,"amount":4189.85048,"timestamp":1766065566355},"postHourTrading":{"tag":"盘后","latestPrice":8.55,"preClose":8.31,"latestTime":"19:24 EST","volume":5286,"amount":44188.1801,"timestamp":1766103868205},"volumeRatio":3.672343,"impliedVol":1.067,"impliedVolPercentile":0.4458},"requestUrl":"/m/hq/s/DMAC","defaultTab":"news","newsList":[{"id":"2592904880","title":"BRIEF-Diamedica Therapeutics Provides Dm199 Preeclampsia Program Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2592904880","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592904880?lang=en_us&edition=fundamental","pubTime":"2025-12-18 22:12","pubTimestamp":1766067122,"startTime":"0","endTime":"0","summary":"BRIEF-Diamedica Therapeutics Provides Dm199 Preeclampsia Program Update Dec 18 (Reuters) - DiaMedica Therapeutics Inc DMAC.O:DIAMEDICA THERAPEUTICS PROVIDES DM199 PREECLAMPSIA PROGRAM UPDATE FOLLOWING","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA7WBSLD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"gpt_icon":0},{"id":"2592041909","title":"DiaMedica Therapeutics Advances DM199 Preeclampsia Clinical Program Following FDA Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2592041909","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592041909?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:45","pubTimestamp":1766065522,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc. has announced the completion of a pre-Investigational New Drug  meeting with the U.S. Food and Drug Administration  regarding a planned study of DM199 for preeclampsia. The FDA requested an additional non-clinical, 10-day modified embryo-fetal development and pre- and postnatal development study in a rabbit model, with results expected by the second quarter of 2026. Additionally, an ongoing Phase 2 investigator-sponsored trial of DM199 in South Africa has dosed over 30 women with late-stage preeclampsia. Interim data from this trial have shown statistically significant reductions in blood pressure and dilation of intrauterine arteries, with no placental transfer of DM199 observed. The full results of the rabbit study are anticipated in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL7KmDGP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"gpt_icon":0},{"id":"2592990907","title":"DiaMedica Therapeutics Inc - FDA Requests Additional Non-Clinical Study for Dm199","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990907","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990907?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:45","pubTimestamp":1766065500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA7WBSLD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMAC","BK4139"],"gpt_icon":0},{"id":"2592721909","title":"DiaMedica Therapeutics Provides Dm199 Preeclampsia Program Update Following Pre-Ind Meeting With FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2592721909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592721909?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:45","pubTimestamp":1766065500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA7WBSLD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMAC","BK4139"],"gpt_icon":0},{"id":"2590369921","title":"10% Owner Jan Stahlberg Reports Acquisition of Common Shares of DiaMedica Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2590369921","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590369921?lang=en_us&edition=fundamental","pubTime":"2025-12-09 06:15","pubTimestamp":1765232151,"startTime":"0","endTime":"0","summary":"Jan Stahlberg, a 10% owner, reported the acquisition of common shares of DiaMedica Therapeutics Inc. The Form 4 was filed by multiple reporting persons, including Jan Stahlberg and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLYgBhP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"10% Owner Jan Stahlberg Reports Acquisition of Common Shares of DiaMedica Therapeutics Inc","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"gpt_icon":0},{"id":"2583502526","title":"Lake Street Sticks to Its Buy Rating for Diamedica Therapeutics (DMAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502526","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583502526?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:35","pubTimestamp":1763130936,"startTime":"0","endTime":"0","summary":"In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Diamedica Therapeutics, with a price target of $14.00. Flaten...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-its-buy-rating-for-diamedica-therapeutics-dmac-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-its-buy-rating-for-diamedica-therapeutics-dmac-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DMAC"],"gpt_icon":0},{"id":"2583850905","title":"Diamedica Therapeutics (DMAC) Initiated with a Buy at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2583850905","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583850905?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:36","pubTimestamp":1763127388,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst initiated coverage with a Buy rating on Diamedica Therapeutics today and set a price target of $25.00. Diamedica Therapeu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/diamedica-therapeutics-dmac-initiated-with-a-buy-at-cantor-fitzgerald-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/diamedica-therapeutics-dmac-initiated-with-a-buy-at-cantor-fitzgerald-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DMAC","BK4139"],"gpt_icon":0},{"id":"2583832695","title":"DiaMedica Therapeutics Q3 Cash & Investments USD 55.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583832695","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583832695?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:30","pubTimestamp":1762983001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXD4F4D0:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMAC","BK4139"],"gpt_icon":0},{"id":"2583583256","title":"DiaMedica Therapeutics Q3 Net Income USD -8.62 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583583256","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583583256?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:30","pubTimestamp":1762983001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXD4F4D0:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMAC","BK4139"],"gpt_icon":0},{"id":"2583408585","title":"DiaMedica Therapeutics Inc - Has $55 Mln Cash With Runway Into 2H 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2583408585","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583408585?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:30","pubTimestamp":1762983001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXD4F4D0:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMAC"],"gpt_icon":0},{"id":"2582393970","title":"Analysts Are Bullish on These Healthcare Stocks: Beyond Air (XAIR), Diamedica Therapeutics (DMAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582393970","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582393970?lang=en_us&edition=fundamental","pubTime":"2025-11-12 00:00","pubTimestamp":1762876821,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Beyond Air (XAIR – Research Report) and Diamedica Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-beyond-air-xair-diamedica-therapeutics-dmac-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-beyond-air-xair-diamedica-therapeutics-dmac-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4581","HCSG","LABU","XBI","BK4588","XLV","BK4585","XAIR","BK4082","BK4112","BK4137","LU0029874061.USD","DMAC","BK4139"],"gpt_icon":0},{"id":"2582871573","title":"DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference in London","url":"https://stock-news.laohu8.com/highlight/detail?id=2582871573","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582871573?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:15","pubTimestamp":1762780524,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, will participate in the Jefferies Global Healthcare Conference in London. President and CEO Rick Pauls is scheduled to deliver a corporate presentation and hold one-on-one investor meetings on November 20, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on November 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbHWVSk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"gpt_icon":0},{"id":"2581787044","title":"Press Release: DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581787044","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581787044?lang=en_us&edition=fundamental","pubTime":"2025-11-07 07:24","pubTimestamp":1762471440,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its third quarter 2025 financial results will be released after the markets close on Wednesday, November 12 . DiaMedica will host a live conference call on Thursday, November 13 at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results.DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant  form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's website at www.diam","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DMAC","LENZ","BK4139","BK4539"],"gpt_icon":0},{"id":"2580225653","title":"DiaMedica Therapeutics Files Initial Statement of Beneficial Ownership for Chief Marketing Officer Julie Krop","url":"https://stock-news.laohu8.com/highlight/detail?id=2580225653","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580225653?lang=en_us&edition=fundamental","pubTime":"2025-11-04 05:32","pubTimestamp":1762205535,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing names Julie Krop, who serves as Chief Marketing Officer, as the reporting beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL4xDLKC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMAC"],"gpt_icon":0},{"id":"2579110447","title":"TD Cowen Initiates DiaMedica Therapeutics at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2579110447","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579110447?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:16","pubTimestamp":1761822994,"startTime":"0","endTime":"0","summary":"TD Cowen Initiates DiaMedica Therapeutics at Buy","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","DMAC","BK4566","COWN","BK4207","TD","BK4585","BK4007","BK4539","LENZ","BK4127"],"gpt_icon":0},{"id":"2571368196","title":"BRIEF-DiaMedica Announces Inducement Grants Under Nasdaq Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2571368196","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571368196?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:42","pubTimestamp":1759178565,"startTime":"0","endTime":"0","summary":"BRIEF-DiaMedica Announces Inducement Grants Under Nasdaq ListingSept 29 (Reuters) - DiaMedica Therapeutics Inc DMAC.O:DIAMEDICA ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nBw2BRLHqaFurther company coverage: DMAC.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUA8TF7WD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"gpt_icon":0},{"id":"2571506233","title":"DiaMedica Therapeutics Grants Stock Options to New Employees Under Amended 2021 Inducement Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2571506233","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571506233?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:15","pubTimestamp":1759176910,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc. has granted stock options to five new non-executive employees who joined the company in August and September 2025. The options allow the purchase of a total of 490,000 shares of DiaMedica's common stock at an exercise price of $6.76 per share, matching the closing price on September 18, 2025. The options vest with 25% becoming exercisable on the one-year anniversary of the grant date, and the remaining 75% vesting in twelve equal quarterly installments over the following three years. The options have a ten-year term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on September 29, 2025, and is solely","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL9pHBF0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"gpt_icon":0},{"id":"2571235069","title":"DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2571235069","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571235069?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:15","pubTimestamp":1759176900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUA8TF7WD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMAC","BK4139"],"gpt_icon":0},{"id":"2565568150","title":"DiaMedica Therapeutics Inc. to Participate in H.C. Wainwright 27th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2565568150","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565568150?lang=en_us&edition=fundamental","pubTime":"2025-09-05 20:30","pubTimestamp":1757075431,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The company's President and CEO, Rick Pauls, along with Chief Business Officer Dave Wambeke, will engage in one-on-one meetings and deliver a corporate presentation on September 9, 2025, from 2:30-3 p.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on September 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL1HCc72:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMAC"],"gpt_icon":0},{"id":"2565304275","title":"Jan Stahlberg, 10% Owner, Reports Acquisition of Common Shares in DiaMedica Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2565304275","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565304275?lang=en_us&edition=fundamental","pubTime":"2025-09-05 02:30","pubTimestamp":1757010603,"startTime":"0","endTime":"0","summary":"Jan Stahlberg, a 10% Owner, reported the acquisition of common shares of DiaMedica Therapeutics Inc. [DMAC]. The form was filed by more than one reporting person, including Jan Stahlberg and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 04, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL2rvhnd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.diamedica.com","stockEarnings":[{"period":"1week","weight":-0.1103},{"period":"1month","weight":0.2043},{"period":"3month","weight":0.2185},{"period":"6month","weight":1.3019},{"period":"1year","weight":0.7241},{"period":"ytd","weight":0.5304}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.052477},{"month":2,"riseRate":0.857143,"avgChangeRate":0.07616},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.098399},{"month":4,"riseRate":0.571429,"avgChangeRate":0.024116},{"month":5,"riseRate":0.571429,"avgChangeRate":0.093378},{"month":6,"riseRate":0.571429,"avgChangeRate":0.181571},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.11728},{"month":8,"riseRate":0.571429,"avgChangeRate":0.048626},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.090818},{"month":10,"riseRate":0.571429,"avgChangeRate":0.039154},{"month":11,"riseRate":0.857143,"avgChangeRate":0.137742},{"month":12,"riseRate":0.571429,"avgChangeRate":0.2518}],"exchange":"NASDAQ","name":"DiaMedica Therapeutics Inc.","nameEN":"DiaMedica Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"DiaMedica Therapeutics Inc.(DMAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest DiaMedica Therapeutics Inc.(DMAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"DiaMedica Therapeutics Inc.,DMAC,DiaMedica Therapeutics Inc.股票,DiaMedica Therapeutics Inc.股票老虎,DiaMedica Therapeutics Inc.股票老虎国际,DiaMedica Therapeutics Inc.行情,DiaMedica Therapeutics Inc.股票行情,DiaMedica Therapeutics Inc.股价,DiaMedica Therapeutics Inc.股市,DiaMedica Therapeutics Inc.股票价格,DiaMedica Therapeutics Inc.股票交易,DiaMedica Therapeutics Inc.股票购买,DiaMedica Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"DiaMedica Therapeutics Inc.(DMAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest DiaMedica Therapeutics Inc.(DMAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}